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IIB-myosin heavy chainAdult-onset autosomal dominant leukodystrophy (ADLD) is a slowly progressive neurological disorder
characterised by pyramidal, cerebellar, and autonomic disturbances. Duplication of the LMNB1 gene is
the genetic cause of ADLD, yet the pathogenetic mechanism is not deﬁned. In this study, we analysed
cells and muscle tissue from three patients affected by ADLD, carrying an extra copy of the LMNB1 gene.
Lamin B1 levels were dramatically increased in ADLD nuclei, both in skin ﬁbroblasts and skeletal muscle
ﬁbres. Since lamin B1 is known to bind Oct-1, a transcription factor involved in the oxidative stress path-
way, we investigated Oct-1 fate in ADLD. Oct-1 recruitment to the nuclear periphery was increased in
ADLD cells, while nucleoplasmic localisation of the transcription factor under oxidative stress conditions
was reduced. Importantly, lamin B1 degradation occurring in some, but not all ADLD cell lines, slowed
down lamin B1 and Oct-1 accumulation. In skeletal muscle, focal disorganisation of sarcomeres was ob-
served, while IIB-myosin heavy chain, an Oct-1 target gene, was under-expressed and rod-containing ﬁ-
bres were formed. These data show that a high degree of regulation of lamin B1 expression is implicated
in the different clinical phenotypes observed in ADLD and show that altered Oct-1 nuclear localisation con-
tributes to the disease phenotype.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
The hereditary leukodystrophies represent a rare group of neuro-
logical disorders, in which partial or total dysmyelination occurs in
either the central nervous system (CNS), the peripheral nervous sys-
tem or both [1]. Leukodystrophies include adult-onset autosomal
dominant leukodystrophy (ADLD, OMIM #169500) ﬁrst described
in 1984 in a large Irish American family [2]. ADLD, a very rare disease,
is characterised by a slowly progressive central nervous system
myelin degeneration with pyramidal, cerebellar and autonomic
disturbances [3,4]. The symptoms begin between the forth to sixth
decades of life with early presentation of autonomic symptoms,
orthostatic hypotension and decreased sweating [4,5]. Autonomic
symptoms precede cerebellar signs and pyramidal abnormalitiesGenetics, Unit of Bologna IOR,
6366394; fax:+39051583593.
rights reserved.[6]. ADLD is caused by duplication of LMNB1 gene encoding lamin
B1 [7] and represents the ﬁrst example of the involvement of lamins
in disorders of the CNS with severe demyelinating phenotype [7,8].
Lamin B1 is a component of nuclear lamina which is a ﬁbrous mesh-
work of intermediate ﬁlaments underlying the inner nuclear mem-
brane [9]. The nuclear lamina is made up of two major types of
lamins, A and B type, based on their sequence homologies, expres-
sion patterns, structural features and biochemical and dynamic
properties. The A-type lamins, including lamins A and C, are derived
from a single gene (LMNA) by alternative splicing and are expressed
in differentiated cells [10]. The B-type lamins, lamin B1 and B2 are
encoded by two separate genes, LMNB1 and LMNB2 and are present
in all cell types including stem cells [10,11]. Lamin B3 is also encoded
by the LMNB2 gene and it is expressed in germ cells only [12]. Lamin
A and B type lamins are translated as precursors and require post-
translational modiﬁcations of their carboxyterminal CAAX box to be-
come mature lamins [13]. In contrast to lamin A, which lacks the
carboxy-terminal farnesyl and carboxymethyl modiﬁcations in the
mature isoform, B-type lamins remain permanently farnesylated
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support and plays dynamic roles in the organisation and regulation
of chromatin, transcription, DNA repair, DNA replication and epige-
netic phenomena of chromatin transitions [10]. The importance
of the nuclear lamina in normal cellular functioning has been
supported by the identiﬁcation of a wide range of human diseases,
collectively called laminopathies, caused by mutations in LMNA or
other genes encoding proteins of the nuclear envelope [10]. More
than 300 human mutations have been identiﬁed in the LMNA gene
and a wide range of clinical phenotypes have been associated with
lamin A/C defects including disorders of the musculoskeletal system,
premature aging, fat metabolism and peripheral nervous system.
Two diseases have been linked to mutations in LMNB1 or LMNB2.
Besides ADLD, a study reported an increased frequency of LMNB2
polymorphisms in patients with acquired partial lypodystrophy [15].
An important mechanism by which the lamins can regulate gene
expression is by associating with speciﬁc transcription factors such
as AP1, c-Fos, MOK2, sterol response element binding protein 1
(SREBP1) [10,16] and the octamer transcription factor (Oct-1) [17].
Lamins are also associated with transcription factors indirectly via
several lamin-binding proteins including emerin and LAP2 [10].
OCT-1 is a ubiquitous transcription factor with activating and silenc-
ing activities and is widely expressed; moreover it is a potent regula-
tor of metabolism and tumourigenicity [18]. In fact, Oct-1 interacts
with BRCA1, a tumour suppressor protein associated with DNA dam-
age response [19]. The association of Oct-1 with lamin B1 at the
nuclear envelope appears to be important for the oxidative stress
response in MEFs, as lamin B1 deﬁciency leads to a dysregulation of
Oct-1-dependent genes and to an increase in reactive oxygen species
[17]. In the study reported in the present paper, performed on human
skeletal muscle tissue and human ﬁbroblast cultures from ADLD
patients, we show that ADLD nuclei from diverse affected subjects
express different levels of lamin B1, irrespective of the gene duplica-
tion event. We ﬁnd that differences in lamin B1 levels are elicited by
different activation of a degradation mechanism, which is differently
efﬁcient in patients. Moreover, recruitment of Oct-1 to the nuclear
periphery parallels lamin B1 accumulation in the nuclear lamina.
Downstream of this event, IIB-myosin heavy chain (IIB-MyHC), a
target of Oct-1 activation, is downregulated to undetectable levels
in ADLD1 muscle. These data contribute to the understanding of the
different clinical phenotypes observed in ADLD.
2. Materials and methods
2.1. Clinical phenotype
2.1.1. Patient 1 (ADLD1)
A 53-year-old man carrying the LMNB1 duplication was evaluated
after two years history of autonomic disturbances (urinary urgency,
ejaculatory failure, and orthostatic intolerance) followed by progressive
lower limb fatigue and poor balance. On admission revealed a symp-
tomatic orthostatic hypotension, cerebellar and pyramidal signs. Car-
diovascular reﬂexes indicated a selective sympathetic failure, sparing
cardiovagal function andmicroneurographic recordings showed absent
muscle sympathetic nerve activity. The evaluation of autonomic inner-
vation of skin annexes revealed abnormal noradrenergic dopamine-
β-hydroxylase (DβH) immunoreactive ﬁbres and preserved cholinergic
vasoactive intestinal polypeptide (VIP) immunoreactive ﬁbres.
2.1.2. Patient 2 (ADLD2)
A 46-year-old man carrying the LMNB1 duplication complains
initial erectile dysfunction. Cardiovascular reﬂexes indicated a selective
sympathetic failure (asymptomatic orthostatic hypotension), sparing
cardiovagal function and microneurographic recordings showed absent
muscle sympathetic nerve activity. The evaluation of autonomic innerva-
tion of skin annexes revealed abnormal noradrenergic dopamine-β-hydroxylase (DβH) immunoreactive ﬁbres and preserved cholinergic
vasoactive intestinal polypeptide (VIP) immunoreactive ﬁbres.
2.1.3. Patient 3 (ADLD3)
A 57-year-old woman carrying the LMNB1 duplication was exam-
ined after seven years history of slowly progressive clumsy gait and
urinary urgency. Neurological examination showed pyramidal signs.
Cardiovascular reﬂexes showed borderline results. Skin biopsy
revealed normal ﬁndings.
In all patients, brain MRI showed a diffuse T2 hyperintensity of the
cerebral white matter with a predominant frontoparietal distribution
and the cardiac autonomic nervous system assessed by means of
123-iodine metaiodobenzylguanidine (123I MIBG) was unremarkable.
The patients underwent an extensive work-up to exclude a demy-
elinating disorder caused by a known metabolic defect. Lysosomal
enzyme activities were normal (exosoaminidase A and B, arysulfatase
A, galactosyl-cerebrosidase, alpha and beta mannosidase) as well as
the very long-chain fatty acids.
2.2. Gene duplication and array-based comparative genomic hybridisation
Genomic DNA was isolated from three conﬂuent ﬁbroblast cultures
derived from ADLD patients, using the DNeasy Blood & Tissue Kit
(QIAGEN GmbH, Hilden, Germany) according to standard methods.
The presence of LMNB1 duplication was assayed through multiplex
PCR coupled with semi-quantitative denaturing high performance
liquid chromatography (DHPLC)-based technique.
Moreover, array-Based Comparative Genomic Hybridisation (array-
CGH) was performed using a whole genome high resolution platform
(CytoChip Oligo ISCA 180 K, BlueGnome, Cambridge, UK). This array
consists of 60-mer oligonucleotides spaced at ~25 kb over the full
genome. The positions of oligomers refer to the Human Genome
March 2006 assembly (hg18). A sex-matched reference DNA (Promega,
Madison, UK) has been used for each sample tested. Digestion, labeling
and hybridisation were performed following the manufacturer's proto-
col (version 1.2) (www.cytochip.com). Slides were scanned using an
Agilent scanner, with a 5 μm resolution. Data were analysed using
BlueFuse Multi Software (BlueGnome, Cambridge, UK).
2.3. Gene expression analysis
Total RNA was isolated using Rneasy Mini Kit (Qiagen GmbH,
Hilden, Germany) from conﬂuent ﬁbroblast cultures following manu-
facturer instructions. RNA was reverse transcribed into cDNA using
the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems,
Monza, Italy). LMNB1 expression was evaluated by Real Time PCR,
performed using an Applied Biosystems StepOne thermal cycler instru-
mentation (Applied Biosystems), by amplifying 1 μg of cDNA and the
TaqMan Gene Expression Assays (Applied Biosystems). Probes and
primers obtained by Applied Biosystems were: GAPDH, assay ID
Hs99999905_m1, LMNB1, assay ID Hs01059210_m1. The ampliﬁcation
protocol was: 50 °C for 2 min; 95 °C for 10 min; 95 °C for 15 s, 60 °C
for 1 min, for 40 cycles. The results were calculated by the 2-ΔΔCT
method. The experiments were performed in quadruplicate.
2.4. Cell culture and treatment
Skin and muscle biopsies were obtained from three consenting
ADLD patients of a large Italian family [6] and were used to establish
primary skin ﬁbroblasts cultures or cryosectioned to analyze protein
localization in mature muscle [20]. Tibialis anterior muscle was
subjected to biopsy. Control muscle biopsies were also obtained
from patients undergoing surgery. All the local and EU ethical issues
were respected.
To block lysosomal activity, chloroquine (Sigma, 25 μM for 20 hours
or 100 μM for 8 hours) was applied. To check proteasome-mediated
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20 hours or 50 μM for 8 hours) was applied. To induce oxidative stress
H2O2 was applied at 50 μM concentration for 24 hours.2.5. Antibodies
The following primary antibodies were used in this work: anti-lamin
B1 (Abcam, cleaved lamin B1) diluted 1:100, anti pre-lamin B1 (Abcam)
diluted 1:100, anti-Oct-1 (Santa Cruz, Sc-232) diluted 1:50, anti-laminin
alpha 2 chain (Novocastra) diluted 1:1000, anti-prelamin A (Santa Cruz,
Sc-6214), diluted 1:100, anti-emerin (Monosan) diluted 1:100, anti-
MyHC (fast IIB) diluted 1:100 (Abnova). Secondary antibodies and
TRITC-conjugated Phalloidin were used 1:100 for 1 hour at room
temperature.2.6. Immunoﬂuorescence analysis
Cells were grown on glass coverslips, and immunoﬂuorescence
stainingwas performed in samplesﬁxed inmethanol for 7 min. Unﬁxed
muscle sections from ADLD1 were subjected to immunoﬂuorescence
labelling. Immunoﬂuorescence microscopy was performed using a
Nikon E600 epiﬂuorescencemicroscope and a Nikon oil-immersion
objective (100× magniﬁcation, 1.3 NA, numerical aperture). Photo-
graphs were taken using a Nikon digital camera (DXm).
A Nikon confocal microscope equipped with argon-helium-neon
lasers was used to obtain optical sections in the z-axis at increments
of 1 μm. All images were taken at similar exposures within an exper-
iment for each antibody. Image quantiﬁcation was performed using
NIS-Element BR2.20 software. Images were processed using Adobe
Photoshop 7.0 software (Adobe Systems Italia, Rome, Italy).2.7. Western blotting
To obtain nuclear fractions, cells detached with trypsin were incu-
bated in cold hypotonic buffer containing 10 mMTris–HCl and protease
inhibitors. Mechanical separation was then performed with a syringe
and centrifugation of nuclei was performed at 1100 r.p.m. for 10 min.
Nuclei were lysed in buffer containing 50 mM Tris–HCl, 1% SDS, 5%
2-mercaptoethanol. Lysates were subjected to SDS-PAGE and western
blot analysis.Western blot analysis was performed on proteins separat-
ed by a 5–20% gradient SDS-PAGE. Immunoblotted bandswere revealed
by the Amersham ECL detection system (Glattbrugg, Switzerland). The
intensity of bands wasmeasured using a GS800 Densitometer (Bio-Rad
Laboratories, Milan, Italy).2.8. Transmission electron microscopy
Muscle tissue from control and an ADLD patient (ADLD 1) was
processed for electron microscopy analysis as previously described
[21]. Brieﬂy, muscle tissue was ﬁxed with 2.5% glutaraldehyde-0.1 M
cacodylate buffer pH 7.4 for 3 h at 4 °C, post-ﬁxed with 1% osmium te-
troxide (OsO4) in cacodylate buffer for 2 h, and dehydrated in an etha-
nol series, inﬁltrated with propylene oxide and embedded in Epon
resin. Ultrathin sections (60 nm thick)were stainedwith uranyl acetate
and lead citrate (10 min each) and were observed at 0° tilt angle with a
Geol Jem 1011 transmission electron microscope, operated at 100 kV.
At least 100 nuclei per sample were observed.2.9. Statistical analysis
Statistical analysis was performed using the Student's t test. Ex-
periments were done in triplicate and differences were considered
statistically signiﬁcant for Pb0.05.3. Results and discussion
3.1. Characterization of LMNB1 duplication in ADLD ﬁbroblasts
Array-based comparative genomic hybridization showed duplica-
tions on chromosome 5q23.2 in all three probands (Fig. S1). Duplica-
tion encompassed the entire LMNB1 gene (OMIM *150340) and
extended over part of the MARCH3 gene (OMIM *613333).
ADLD1 and ADLD3 showed the same duplication, sizing about
315 kb, from A_16_P17291318 (126,074,935 bp) to A_14_P138571
(126,390,260 bp) respectively, instead ADLD2 showed a smaller du-
plication sizing about 235 kb, from A_16_P17291401 (126,125,592)
to A_16_P17292003 (126,360,712 bp) (UCSC genome Browser;
http://genome.ucsc.edu/; hg18 release) (Fig. S1).
3.2. Lamin B1 increase in the nuclear lamina of ADLD ﬁbroblasts
Prelamin B1 and lamin B1 levels were determined in skin ﬁbro-
blasts from two severely affected ADLD patients (ADLD 1 and 2) and
a patient from the same family showing a milder clinical phenotype
(ADLD 3). Prelamin B1 levels were not changed in ADLD nuclei with
respect to controls (Fig. 1a–d). However, mature lamin B1 staining
was highly increased at the nuclear lamina in ADLD 1 and ADLD2,
while it was moderately increased in ADLD 3 nuclei (Fig. 1e–h).
Lamin A/C was not affected in ADLD cells, being expressed at levels
comparable to controls (Fig. 1i–l). We hypothesised that prelamin A
processing could be also affected in ADLD nuclei due to prelamin B
overload, since at least a processing enzyme, the RCE1, can be shared
by prelamin B and A. Prelamin A levels (Fig. 1m–p) were moderately
increased in cells showing high levels of lamin B1, but not in ADLD 3
nuclei, showing normal lamin B1 amount.
Nuclear enlargement was observed in 9% of ﬁbroblast nuclei, but
rare dysmorphic nuclei were scored (Fig. 1q–t). Quantitative analysis
and western blotting of ADLD ﬁbroblast nuclei conﬁrmed a signiﬁcant
increase of lamin B1 levels in ADLD 1 and 2, but not in ADLD 3
(Fig. 1u, v). In addition, RT-PCR analysis showed that LMNB1 mRNA
levels were increased in all the examined cell lines, irrespective of dif-
ferent protein levels and disease severity (Fig. 1w). Two major ﬁnd-
ings were obtained from our experiments. First, prelamin B1
processing appears to be accelerated in cells overexpressing the
LMNB1 gene, since protein levels are not enhanced, despite the rele-
vant increase of the mature lamin B1 form. Thus, as previously
suggested [14,17], a highly efﬁcient processing machinery avoids ac-
cumulation of prelamin B1 in nuclei, thus reducing possible toxic
effects. Secondly, despite the presence of LMNB1 duplications in the
three ADLD patients here examined, lamin B1 levels are maintained
at normal levels in the patient showing a mild clinical phenotype,
although this individual presents the same copy number as the
most severely affected subject (Fig. S1). Overall, it appears that
there is a high degree of lamin B1 regulation even in the most severe
ADLD cases, as suggested by the moderate increase of protein level
with respect to the relevant difference in mRNA expression. In this
context, the activation of a mechanism leading to partial protein
degradation appeared likely, as shown below.
3.3. Lamin B1 degradation in ADLD
In fact, the reason why diverse ADLD cell cultures and tissues
show different levels of lamin B1, has been elusive. To check the pos-
sible onset of a degradation mechanism, we treated ADLD ﬁbroblasts
from the three patients and controls with protease inhibitors and
evaluated lamin B1 staining in cells. Fig. 2 (panels a–l) shows that
treatment of ADLD1and ADLD2 with protease inhibitors MG132 or
chloroquine did not affect lamin B1 ﬂuorescence intensity, while
lamin B1 levels were increased in ADLD3 cells following either treat-
ment (Fig. 2j–l). The quantitative analysis supported these ﬁndings
Fig. 1. Lamin expression in ADLD ﬁbroblasts. Prelamin B1 (a–d), lamin B1 (e–h), lamin A/C (i–l) and prelamin A (m–p) were immunolabelled using speciﬁc primary antibodies and
TRITC- (a–l) or FITC- (m–p)conjugated secondary antibodies. Nuclei shown in (m–p) were counterstained using DAPI (q–t). Scale bars 10 μm. Lamin B1 ﬂuorescence intensity was
measured using NIS software and data from three different measurements are plotted in panel u. Data represent the mean±SD. Western blot analysis of lamin B1 in ﬁbroblast nu-
clei is shown and densitometry values of lamin B1 bands are plotted as means of three different analyses±SD (v). Emerin western blot analysis was performed as a loading control.
LMNB1 mRNA expression was measured by quantitative RT-PCR (w). 2-ΔΔcT values are reported relative to control samples. Statistical analysis (in u–w) was performed using
Student's t-test, P values indicate the statistical signiﬁcance (reported in red).
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Fig. 2. Lamin B1 degradation in ADLD ﬁbroblasts. Lamin B1 immunoﬂuorescence staining in control (a–c) or ADLD ﬁbroblasts (d–l) left untreated (a, d, g, j) or treated with MG132
to inhibit proteasome-mediated degradation (b, e, h, k) or chloroquine (CQ) to inhibit lysosomal activity (c, f, i, l). Lamin B1 ﬂuorescence intensity was measured using the NIS
software and data obtained from triplicate measurements were plotted as means±standard deviation of three independent experiments (m). P values (in red) indicate statistically
signiﬁcant increase of lamin B1 ﬂuorescence in inhibitor-treated ADLD3 cells. NT, not treated. Scale bars, 10 μm.
415M. Columbaro et al. / Biochimica et Biophysica Acta 1832 (2013) 411–420(Fig. 2m). A shorter treatment with protease inhibitors also elicited
lamin B1 increase, though at less signiﬁcant levels. These data indi-
cate that lamin B1 levels are kept normal in ADLD patients by a deg-
radation mechanism, which appears to be insufﬁcient in some
patients, thus allowing protein accumulation and possibly disease
progression. The involvement of both proteasome-mediated degrada-
tion and lysosomal activity in the regulation of lamin B1 levels in
ADLD is indicated by the efﬁcacy of both inhibitory treatments. How-
ever, the involvement of other mechanisms of lamin B1 regulation,
including miR-23-mediated down-regulation, previously shown in
olygodendrocytes [22], cannot be ruled out.
3.4. Nuclear defects in ADLD muscle
While control muscle nuclei were mostly ovoid and chromatin was
well organized (Fig. 3a), a percentage of nuclei from an ADLD1 muscle
biopsy were enlarged and misshapen, with areas of heterochromatinloss (Fig. 3b). Immunoﬂuorescence labelling showed that lamin B1
levels were signiﬁcantly increased in myonuclei and interstitial cell nu-
clei (Fig. 3c–f), while prelamin B1 staining was not affected (Fig. 3g–h).
Prelamin A levels were not increased in muscle nuclei (Fig. 3i–j). Quan-
titative analysis supported the results showing lamin B1 increase
(Fig. 3k). Thus, our data suggested that nuclear defects were indeed
present in ADLDmuscle due to lamin B1 upregulation and could poten-
tially affect muscle function, as shown below.
3.5. Oct-1 accumulation in ADLD nuclei
To unravel the pathogenetic signiﬁcance of lamin B1 increase in
ADLD, we examined Oct-1, a transcription factor known to bind
lamin B1 [17] in the nuclear envelope and involved in several path-
ways regulating oxidative stress and cellular differentiation [17,18].
Oct-1 localized at the nuclear lamina of both control and ADLDﬁbro-
blasts and mostly in the nucleoplasm of control ﬁbroblasts (Fig. 4a–d).
Fig. 3. Nuclear defects in ADLD skeletal muscle. Transmission electron microscopy analysis of control (a) or ADLD1 skeletal muscle (b). Nuclear enlargement and misshapening is
observed in ADLD1 (b). Scale bar, 1 μm. Lamin B1 immunoﬂuorescence staining of frozen sections from control (c, e) and ADLD1 skeletal muscle (d, f). Prelamin B1 (g, h) and
prelamin A (i, j) labelling in control (g, i) or ADLD1 muscle (h, j) is shown. Scale bars, 10 μm. Lamin B1 ﬂuorescence intensity was measured in skeletal muscle sections using
the NIS Software (Nikon). Mean values±standard deviation of three different measurements in three different sections are reported in (k). P value (in red) indicates statistical
signiﬁcance.
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which also showed lamin B1 increase (Fig. 4b, c, f, g). Quantitative anal-
ysis conﬁrmed that in a signiﬁcant percentage of nuclei Oct-1 was
recruited to the nuclear envelope (Fig. 4m).
Next, we examined lamin B1 and Oct-1 localization in skeletal mus-
cle. Oct-1 increase at the nuclear envelopewas observed in ADLD1mus-
cle (Fig. 4n–o and x–z'), but not in ADLD3. Thus, a marked increase of
Oct-1 staining was observed at the nuclear envelope of ADLD 1 and
ADLD 2 cells from the severely affected patients, while the transcription
factor was expressed in ADLD 3 nuclei at levels comparable to controls.
This result indicates Oct-1 as a candidate biomarker of ADLD progres-
sion and again links nuclear envelope recruitment of the transcription
factor to lamin B1 interaction [17]. In agreement with data reported
above, inhibition of lamin B1 degradation elicited an increase of Oct-1
levels even in ADLD3 (Fig. 4p–w). Thus, activation of a degradation
pathway appears to avoidworsening of the phenotype, as it contributes
to keep low levels of Oct-1 recruitment.3.6. Recruitment of Oct-1 in skeletal muscle is associated with IIB-MyHC
downregulation and rod formation
We can conclude that some lamin B1-mediated events might
exert pathogenetic effects not only in the known ADLD target tissues,
such as the myelin ﬁbres and the nervous cells, but also in muscle. A
role of Oct-1 in myosin heavy chain induction during myoblast dif-
ferentiation had been previously suggested [23]. This aspect has
been deepened in the study reported in Fig. 5. In ADLD1 muscle, sev-
eral rod bodies were observed (Fig. 5b, e). These structures are
formed in diseases caused by actin or coﬁlin mutations, but are also
observed in other neuromuscular disorders possibly due to altered
actin turnover [24]. A possible mediator of actin depolymerization/
repolymerization is IIB-MyHC [25], which we found to be almost
completely absent from ADLD1 muscle (Fig. 5c, d). Thus, it is con-
ceivable that altered Oct-1-dependent transactivation of IIB-MyHC
could impair proper protein expression and affect actin turnover
Fig. 4. Oct-1 recruitment to the nuclear envelope in ADLD. Oct-1 staining in control (a) and ADLD cultured ﬁbroblasts (b–d). FITC-conjugated secondary antibody (green) was used
to reveal antibody labelling. Double-immunoﬂuorescence labelling with anti-lamin B1 antibody was performed. Lamin B1 staining was revealed using TRITC-conjugated secondary
antibody (red) in control (e) and ADLD ﬁbroblasts (f–h). DAPI staining of nuclei is shown in (i–l). Nuclei showing Oct-1 staining at the nuclear rim were scored and the percentage
of nuclei (out of 200 counted)±standard deviation is reported in (m). Fluorescence intensity of control nuclear rim was set at zero. (n–o) Localization of Oct-1 in control (n) or
ADLD1 skeletal muscle ﬁbres (o). Oct-1 was revealed using FITC-conjugated secondary antibody (green), laminin alpha 2 was labelled (red) to show sarcolemma. DAPI staining
was used to show nuclei. Oct-1 (p–u) and lamin B1 (p'–u') double immunoﬂuorescence labelling was performed in MG132- or chloroquine-treated (CQ) control (p–r, p'–r') or
ADLD3 ﬁbroblasts (s–u, s'–u'). Oct-1 was revealed using a FITC-conjugated secondary antibody (green), lamin B1 was revealed by TRITC-conjugated secondary antibody (red).
Scale bars, 10 μm. ADLD3 nuclei showing Oct-1 staining at the nuclear rim were scored and the percentage of nuclei before (NT) and after inhibitor treatment (MG132, +CQ)
(out of 200 counted)±standard deviation is reported in (w, upper graph). In the lower graph (w) the ratio between peripheral nuclear ﬂuorescence signal for Oct-1 and nucleo-
plasmic signal is reported. Values were measure by confocal microscopy using a mask to select the nuclear periphery and 200 nuclei were scored from slides shown in (p–u). The
Student's t test was used to calculate P values (in red).
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tures (Fig. 5g).
3.7. Recruitment of Oct-1 in the nuclear lamina reduces its nuclear import
under oxidative stress
The effect of Oct-1 recruitment in the nuclear lamina was tested
under oxidative stress conditions. In fact, Oct-1 has been shown to
be involved in the oxidative stress response [17,26]. In control cul-
tured ﬁbroblasts subjected to H2O2 treatment, Oct-1 staining was
increased in the nucleoplasm, while nuclear rim labelling was notFig. 5. Rod bodies formation in ADLD muscle. Control (a, c) or ADLD muscle sections (b, 6
subjected to immunoﬂuorescence labelling with anti-IIB-myosin heavy chain antibody (c, d
heads in b). IIB-myosin heavy chain was almost undetectable in ADLD1 muscle (d). Scale ba
electron microscopy analysis of ADLD1 skeletal muscle (e, f) showing small rod formation
Based on published data [23,32,33] and on our results here reported, we propose a model
chain leading to its upregulation in certain muscle ﬁbers. IIB-myosin heavy chain contrib
the nuclear lamina, which reduces its DNA binding and transactivation activity and cau
remodelling and cause formation of rod-like structures containing ﬁlamentous actin.detectable (Fig. 6a–c). Conversely, nucleoplasmic staining was less
evident in ADLD1 and ADLD2 cells, which preserved nuclear rim
labelling (Fig. 6d–j). ADLD3 cells did not signiﬁcantly differ from
controls in the vast majority of nuclei, although nuclear rim loca-
lization of Oct-1 was also observed in a low percentage of nuclei
(Fig. 6i–m). These data, in agreement with previously published results
showing that excess levels of Oct-1 import in LMNB1 knockout cells trig-
ger ROS production [17], indicate that the oxidative stress response
might be altered in ADLD cells, if lamin B1 is accumulated in nuclei. Al-
tered oxidative stress response has been linked to other diseases of the
nuclear lamina and appears to contribute to the pathogenetic pathways) were stained using TRITC-conjugated phalloidin to stain ﬁlamentous actin (a, b) or
). 15% of ADLD1 muscle ﬁbres (out of 100 examined) presented rod formation (arrow-
r in b (10 μm) refers to a and b; scale bar in d (10 μm) refers to c and d. Transmission
s (arrowheads in e) and sarcomere disorganization (f). Scale bar for e and f, 1 μm. (g)
whereby, in control muscle, Oct-1 binds to DNA and transactivates IIB-myosin heavy
utes to the process of sarcomere remodelling. In ADLD1 muscle, Oct-1 is recruited to
ses downregulation of IIB-MyHC. The absence of IIB-MyHC may impair sarcomere
Fig. 6. Oct-1 localization in ADLD cells subjected to oxidative stress. Control (a–c) or ADLD ﬁbroblasts (d–m) were left untreated (NT) or treated with 50 μM H2O2 for 24 hours
(H2O2). Oct-1 localization is shown in nuclei. High magniﬁcation of the nuclear envelope (indicated by white arrowheads) is shown in the right lane (c, f, j, m) to allow visualization
of nucleoplasmic or peripheral Oct-1. Scale bar, 10 μm.
419M. Columbaro et al. / Biochimica et Biophysica Acta 1832 (2013) 411–420[27]. In our experimental conditions, we did not observe changes in
the levels of stress response factors in ADLD, although ADLD1 cells
expressing high levels of lamin B1 showed reduced proliferation
activity. However, given that high lamin B1 levels have been linked
to ROS induction and cellular senescence [28], a synergistic effect of
lamin B1 up-regulation and altered Oct-1 nuclear import, leading to
improper regulation of response factors, could induce oxidative
stress-triggered cell death [29]. This deserves further studies, as it
could contribute to the demyelization process that affects ADLD
patients.
Our data support the role of the nuclear lamina as a transcription
factor resting place, previously demonstrated for Oct-1 [17]. Howev-
er, altered Oct-1 nuclear import might have pleiotropic effects [26],
with diverse pathogenetic signiﬁcance depending on each tissue
[30]. For instance, we observed Oct-1 accumulation at the myotube
nuclear envelope (not shown), a ﬁnding that argues in favour of
Oct-1 involvement in muscle differentiation [23]. It could be relevant
to explore the role of Oct-1 during speciﬁcation and differentiation of
different precursors. Although the pathogenetic effect of Oct-1
increase in oligodendrocytes, the best recognised target cells in
ADLD, remains to be deﬁned, it has been demonstrated that LMNB1
overexpression in oligodendrocytes elicits downregulation of
differentiation-related genes [22]. Oct-1 could be a mediator of this
effect, thus impairing myelin formation.
The whole evaluation of the results here reported, allows us to
suggest that the use of drugs capable of activating lamin B1 degrada-
tion, such as calphostin [31] or analogous compounds, could be tested
in ADLD cells for their ability to counteract both protein accumulation
and altered transcription factor recruitment.Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbadis.2012.12.006.Acknowledgements
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